Blue March: Understanding Colorectal Cancer Screening

Colorectal cancer is a significant health concern in France, representing the third most common cancer and the second leading cause of cancer-related deaths. Still, early detection and removal of precancerous growths, known as adenomatous polyps, can dramatically reduce risk and even prevent the disease from developing. This March, designated “Blue March,” focuses on raising awareness about colorectal cancer screening and encouraging participation to improve outcomes.

The Importance of Screening

In over 80% of cases, colorectal cancer develops from benign tumors (adenomatous polyps). The Ligue contre le cancer emphasizes that detecting and removing these polyps can significantly lower the risk of cancer or eliminate it altogether. When diagnosed at an early stage, approximately 9 out of 10 colorectal cancer cases are curable, particularly with the use of immunological testing.

Who is at Risk?

While anyone can develop colorectal cancer, the risk increases with age. 95% of cases occur in individuals over 50 years old, with a median diagnosis age of 71 for men and 72 for women. The CNMSS reports that France sees over 47,000 new cases each year, resulting in 17,000 deaths.

The FIT Test: A Simple Screening Method

Since 2015, the Fecal Immunochemical Test (FIT) has been available in France through your doctor, pharmacist, or via your Ameli account. This test is a quick and convenient way to check for blood in the stool, a potential indicator of polyps or cancer. It involves collecting a small stool sample with a swab and sending it to a laboratory for analysis.

The FIT test is recommended for individuals between the ages of 50 and 74 who have no family history of colon cancer and are considered at average risk. It should be performed every two years. If you have concerns or a family history, consult your doctor.

What Happens After a Positive Test?

A positive FIT test does not necessarily mean you have cancer. In fact, the Ligue contre le cancer states that 96% of screening results are negative. However, a positive result warrants further investigation, typically a colonoscopy, to identify the source of the bleeding and determine if any polyps or cancer are present.

The Impact of Early Detection: A Personal Story

Early detection can significantly improve treatment outcomes. One individual, Pierre Estellon, diagnosed with colorectal cancer 11 years ago following screening, shared his experience. While his screening was unfortunately realized too late, requiring extensive treatment including chemotherapy, radiotherapy, and surgery, he now actively participates in the association Provence Stomie Contact, offering support to others facing similar challenges. His story highlights the importance of timely screening and the hope for a return to a normal life even after a cancer diagnosis.

Increasing Screening Rates

Despite the benefits of screening, participation rates remain relatively low in France, at around 30%. Efforts are underway to increase this to 45%, aligning with European averages. Raising awareness and encouraging individuals to undergo screening are crucial steps in reducing colorectal cancer mortality.

Get Involved and Learn More

This March, join the Blue March movement by spreading awareness and encouraging your loved ones to get screened. For more information, visit www.depistage-cancers-sud.org.